Drugs / supCD7 CART cells
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT07153068 | Jun 2025 → Jun 2028 expected | T lymphoblastic leukemia/lymphoma, acute myeloid leukemia | Institute of Hematology & Blood Diseases Hospital, China | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | supCD7 CART cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07153068 ↗ |
| Modality | Cell therapy | “Biological: supCD7 CART cells” NCT07153068 ↗ |
| Route | Intravenous | “supCD7 CART cells will be administered intravenously” NCT07153068 ↗ |
| Target | CD7 | “This study will use super-universal CD7 CART cells to treat CD7-positive relapsed or refractory hematological malignancies” NCT07153068 ↗ |